scholarly journals Association between long non-coding RNA (lncRNA) GAS5 polymorphism rs145204276 and cancer risk

2021 ◽  
Vol 49 (9) ◽  
pp. 030006052110397
Author(s):  
Shushan Zhao ◽  
Ping Liu ◽  
Zhe Ruan ◽  
Jianhuang Li ◽  
Shan Zeng ◽  
...  

Objective The long non-coding RNA (lncRNA) growth arrest‑specific transcript 5 (GAS5) plays an important role in various tumors, and an increasing number of studies have explored the association of the GAS5 rs145204276 polymorphism with cancer risk with inconclusive results. Methods PubMed, Medline, EMBASE, Cochrane databases, and Web of Science were searched, and nine studies involving 6107 cases and 7909 controls were deemed eligible. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated to evaluate the relationship between rs145204276 and cancer risk in six genetic models. Results The pooled results suggest that the variant allele del was not associated with overall cancer risk. However, the subgroup analysis showed that allele del was significantly associated with a 22% decreased risk of gastrointestinal cancer (OR = 0.78, 95% CI: 0.72–0.85). Both sensitivity analyses and trial sequential analyses (TSA) demonstrated that the subgroup results were reliable and robust. Moreover, False-Positive Report Probability (FPRP) analysis indicated that the results had true significant correlations. Conclusion These findings provide evidence that the GAS5 rs145204276 polymorphism is associated with the susceptibility to gastrointestinal cancer. Further studies with different ethnicities and larger sample sizes are warranted to confirm these results.

2020 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Saeid Ghavami ◽  
Mohsen Taheri ◽  
Mohammad Hashemi

Objectives: Several studies have reported a correlation between the POLR2E rs3787016 polymorphism and cancer development, but findings are inconsistent. Therefore, we designed the current study to understand how rs3787016 polymorphism impacts cancer susceptibility. Methods: We searched the Scopus, Web of Science, and PubMed databases for studies related to the topic of interest published up to March 2019. A total of 11 relevant studies, encompassing 8,761 cancer cases and 10,534 controls, were retrieved and subject to quantitative analysis. The strength of the relationship was evaluated using the pooled odds ratios (ORs) with 95% confidence intervals (CIs). Results: Overall, the findings proposed a positive association between rs189037 polymorphism and susceptibility to cancer in homozygous (OR = 1.32, 95% CI = 1.11 - 1.57, P = 0.002, TT vs. CC), recessive (OR = 1.21, 95% CI = 1.06-1.39, P = 0.005, TT vs. CT + CC), and allele (OR = 1.12, 95% CI = 1.02-1.22, P = 0.021, T vs. C) genetic models. Stratified analysis showed that rs3787016 increased the risk of prostate and breast cancer. In addition, we found a significant association between the variant and increased cancer risk in Asian and Caucasian populations. Conclusions: In summary, the findings of the current meta-analysis suggest that the POLR2E rs3787016 polymorphism is an indicator of cancer susceptibility.


2020 ◽  
Author(s):  
Lijun Lei ◽  
Lianbing Sheng ◽  
Lingyuan Wu ◽  
Jiaojing Liu ◽  
Bin Wei ◽  
...  

Abstract Background We performed this meta-analysis to elucidate whether the expression of PlncRNA-1 might serve as an effective prognostic marker for various cancers. Methods We conducted a database search of PubMed, ScienceDirect, Embase, Web of Science and CNKI database (up to Oct 31, 2019). The pooled hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) were used to estimate the strength of the relationship between PlncRNA-1 expression and the clinical prognosis of cancer patients. Results The results showed that elevated PlncRNA-1 expression predicted a poor OS with pooled HRs of 1.43 (95% CI: 1.25-1.63, I 2 =63.1%, P=0.004). Likewise, we found that advanced tumour stages were associated with upregulated PlncRNA-1 expression in various cancer types (III–IV vs I–II: OR=2.79, 95% CI: 1.76-4.41, I 2 =0%, P=0.822),patients with high PlncRNA-1 expression might have an increased risk of large tumours (OR=2.03, 95% CI: 1.31-3.14, I 2 =67.1%, P=0.028). Conclusions PlncRNA-1 might be used as a prognostic biomarker and as a tool for the early detection of various tumours.


2018 ◽  
Vol 38 (4) ◽  
Author(s):  
Xin Huang ◽  
Weiyue Zhang ◽  
Zengwu Shao

Several studies have suggested that long non-coding RNA (lncRNA) gene polymorphisms are associated with cancer risk. In the present study, we conducted a meta-analysis related to studies on the association between lncRNA single-nucleotide polymorphisms (SNPs) and the overall risk of cancer. A total of 12 SNPs in five common lncRNA genes were finally included in the meta-analysis. In the lncRNA antisense non-coding RNA (ncRNA) in the INK4 locus (ANRIL), the rs1333048 A/C, rs4977574 A/G, and rs10757278 A/G polymorphisms, but not rs1333045 C/T, were correlated with overall cancer risk. Our study also demonstrated that other SNPs were correlated with overall cancer risk, namely, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1, rs619586 A/G), HOXA distal transcript antisense RNA (HOTTIP, rs1859168 A/C), and highly up-regulated in liver cancer (HULC, rs7763881 A/C). Moreover, four prostate cancer-associated ncRNA 1 (PRNCR1, rs16901946 G/A, rs13252298 G/A, rs1016343 T/C, and rs1456315 G/A) SNPs were in association with cancer risk. No association was found between the PRNCR1 (rs7007694 C/T) SNP and the risk of cancer. In conclusion, our results suggest that several studied lncRNA SNPs are associated with overall cancer risk. Therefore, they might be potential predictive biomarkers for the risk of cancer. More studies based on larger sample sizes and more lncRNA SNPs are warranted to confirm these findings.


2020 ◽  
Author(s):  
Qin Lei ◽  
Zhao Jiawen ◽  
Zhao Yutong ◽  
Ma Chenjun ◽  
Li Chaobin ◽  
...  

Abstract BACKGROUND: Rs4778889 T>C is one of the single nucleotide polymorphisms (SNPs) in interleukin-16 (IL-16). As a growth factor, IL-16 might play a significant impact on cancer formation. Several studies have investigated the relationship between IL-16 rs4778889 T>C gene polymorphisms and cancer risk, but the results are contradictory. We conducted a meta-analysis on the association between IL-16 rs4778889 T>C gene polymorphism and cancer risk. METHODS: Twelve case–control studies with 3066 cases and 4433 controls from Web of Science, PubMed, and Embase databases were included. The data was analyzed using the STATA software and the combined odds ratio (ORs) and the corresponding 95% confidence interval (CIs) were used to identify the correlation strength. RESULTS: Our results show that no significant associations were observed between the IL-16 rs4778889 T>C gene polymorphisms and cancer risk in all genetic models (C vs. T: OR=1.06, 95% CI: 0.90–1.26, Ph<0.001; CC vs. TT: OR=1.07, 95% CI: 0.71–1.62, Ph<0.001; CT vs. TT: OR=1.07, 95% CI: 0.91–1.26, Ph=0.002; CC+CT vs. TT: OR=1.08, 95% CI: 0.90–1.30, Ph<0.001; CC vs. CT+TT: OR=1.04, 95% CI: 0.73–1.50, Ph=0.001). Subgroup and sensitivity analyses also were performed. CONCLUSIONS: The results of this meta-analysis indicate that there are no significant associations between IL-16 rs4778889 T>C gene polymorphisms and cancer risk. To verify these results, further studies with larger sample size and multiracial populations are needful. Keywords: IL-16, polymorphisms, cancer, meta-analysis


2020 ◽  
Vol 26 ◽  
Author(s):  
Bei Wang ◽  
Wen Xu ◽  
Yuxuan Cai ◽  
Chong Guo ◽  
Gang Zhou ◽  
...  

Background: CASC15, one of long non-coding RNA, is involved in the regulation of many tumor biological processes, and is expected to become a new biological therapeutic target. This paper aims to elucidate the pathophysiological function of CASC15 in various tumors. Methods: The relationship between CASC15 and tumors was analyzed by searching references, and summarizes the specific pathophysiological mechanism of CASC15. Results: LncRNA CASC15 is closely related to tumor development, and has been shown to be abnormally high expressed in all kinds of tumors, including breast cancer, cervical cancer, lung cancer, hepatocellular carcinoma, gastric cancer, bladder cancer, colon cancer, colorectal cancer, cardiac hypertrophy, intrahepatic cholangiocarcinoma, leukemia, melanoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma. However, CASC15 has been found to be downexpressed abnormally in ovarian cancer, glioma and neuroblastoma. Besides, it is identified that CASC15 can affect the proliferation, invasion and apoptosis of tumors. Conclusion: LncRNA CASC15 has the potential to become a new therapeutic target or marker for a variety of tumors.


BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Wenchao Zhang ◽  
Xiaolei Ren ◽  
Lin Qi ◽  
Chenghao Zhang ◽  
Chao Tu ◽  
...  

Abstract Background In recent years, emerging studies have demonstrated critical functions and potential clinical applications of long non-coding RNA (lncRNA) in osteosarcoma. To further validate the prognostic value of multiple lncRNAs, we have conducted this updated meta-analysis. Methods Literature retrieval was conducted by searching PubMed, Web of Science and the Cochrane Library (last update by October 2, 2019). A meta-analysis was performed to explore association between lncRNAs expression and overall survival (OS) of osteosarcoma patients. Relationships between lncRNAs expression and other clinicopathological features were also analyzed respectively. Results Overall, 4351 patients from 62 studies were included in this meta-analysis and 25 lncRNAs were identified. Pooled analyses showed that high expression of 14 lncRNAs connoted worse OS, while two lncRNAs were associated with positive outcome. Further, analysis toward osteosarcoma clinicopathologic features demonstrated that overexpression of TUG1 and XIST indicated poor clinical parameters of patients. Conclusions This meta-analysis has elucidated the prognostic potential of 16 lncRNAs in human osteosarcoma. Evidently, desperate expression and functional targets of these lncRNAs offer new approaches for prognosis and therapy of osteosarcoma.


2021 ◽  
Author(s):  
Weiwei Chen ◽  
Yuting Li ◽  
Liliangzi Guo ◽  
Chenxing Zhang ◽  
Shaohui Tang

Background: Several studies have assessed the relationship between long non-coding RNA five prime to Xist (FTX) expression, clinicopathological features, and survival outcomes in cancer patients with conflicting results. This meta-analysis synthesized existing data to clarify the association between FTX with cancer prognosis.Methods: PubMed, Embase, Cochrane library, Web of Science, Chinese CNKI, and the Chinese WanFang databases were used to search for relevant studies. Role of FTX in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs).Results: Eleven studies comprising 1,210 participants including colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastric cancer (GC), renal cell carcinoma (RCC), osteosarcoma (OSC), and glioma were enrolled in this analysis. The meta-analysis showed that high FTX expression was significantly associated with several clinicopathological characteristics, including lymph node metastasis in patients with CRC, GC, HCC, and RCC, distant metastasis in patients with CRC, GC, HCC, and OSC, larger tumor size in patients with CRC, GC, HCC, RCC, and OSC, and subsequently TNM/clinical stage in patients with CRC, GC, HCC, OSC, and glioma. The pooled results from the survival analysis revealed a significant correlation between high FTX expression and shorter OS in patients with HCC, CRC, GC, OSC, and glioma. Further, FTX overexpression could be an independent predictive marker for shorter OS in patients with CRC, HCC, OSC, and glioma. Conclusions: FTX may be a potential oncogene, with high FTX expression being associated with a poorer prognosis in patients with CRC, HCC, OSC, and glioma


2020 ◽  
Vol 49 (D1) ◽  
pp. D165-D171
Author(s):  
Lianhe Zhao ◽  
Jiajia Wang ◽  
Yanyan Li ◽  
Tingrui Song ◽  
Yang Wu ◽  
...  

Abstract NONCODE (http://www.noncode.org/) is a comprehensive database of collection and annotation of noncoding RNAs, especially long non-coding RNAs (lncRNAs) in animals. NONCODEV6 is dedicated to providing the full scope of lncRNAs across plants and animals. The number of lncRNAs in NONCODEV6 has increased from 548 640 to 644 510 since the last update in 2017. The number of human lncRNAs has increased from 172 216 to 173 112. The number of mouse lncRNAs increased from 131 697 to 131 974. The number of plant lncRNAs is 94 697. The relationship between lncRNAs in human and cancer were updated with transcriptome sequencing profiles. Three important new features were also introduced in NONCODEV6: (i) updated human lncRNA-disease relationships, especially cancer; (ii) lncRNA annotations with tissue expression profiles and predicted function in five common plants; iii) lncRNAs conservation annotation at transcript level for 23 plant species. NONCODEV6 is accessible through http://www.noncode.org/.


2020 ◽  
Vol 10 ◽  
Author(s):  
Águeda Martínez-Barriocanal ◽  
Diego Arango ◽  
Higinio Dopeso

Sign in / Sign up

Export Citation Format

Share Document